Browsing Clinical Studies by author "Yap, Christina"
Now showing items 41-47 of 47
-
The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.
O'Sullivan, JM; Hamblin, A; Yap, C; Fox, S; Boucher, R; et al. (AMER SOC HEMATOLOGY, 2019-12-05)Essential Thrombocythemia (ET) patients at high-risk of thrombosis require cytoreductive treatment, typically with hydroxycarbamide. Many patients are resistant or intolerant to hydroxycarbamide (HC-RES/INT) and are at ... -
TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis.
Cole, M; Yap, C; Buckley, C; Ng, WF; McInnes, I; et al. (BMC, 2021-07-06)BACKGROUND: Adaptive model-based dose-finding designs have demonstrated advantages over traditional rule-based designs but have increased statistical complexity but uptake has been slow especially outside of cancer trials. ... -
Transplantation of discarded livers following viability testing with normothermic machine perfusion.
Mergental, H; Laing, RW; Kirkham, AJ; Perera, MTPR; Boteon, YL; et al. (NATURE PORTFOLIO, 2020-06-16)There is a limited access to liver transplantation, however, many organs are discarded based on subjective assessment only. Here we report the VITTAL clinical trial (ClinicalTrials.gov number NCT02740608) outcomes, using ... -
Trends in patient-reported outcome use in early phase dose-finding oncology trials - an analysis of ClinicalTrials.gov.
Lai-Kwon, J; Yin, Z; Minchom, A; Yap, C (WILEY, 2021-11-01)BACKGROUND: Patient-reported adverse events (AEs) may be a useful adjunct to clinician-assessed AEs for assessing tolerability in early phase, dose-finding oncology trials (DFOTs). We reviewed DFOTs on ClinicalTrials.gov ... -
Using Patient-Reported Outcomes in Dose-Finding Oncology Trials: Surveys of Key Stakeholders and the National Cancer Research Institute Consumer Forum.
Lai-Kwon, J; Vanderbeek, AM; Minchom, A; Lee Aiyegbusi, O; Ogunleye, D; et al. (OXFORD UNIV PRESS, 2022-09-02)BACKGROUND: Patient-reported adverse events may be a useful adjunct for assessing a drug's tolerability in dose-finding oncology trials (DFOT). We conducted surveys of international stakeholders and the National Cancer ... -
When to keep it simple - adaptive designs are not always useful.
Wason, JMS; Brocklehurst, P; Yap, C (BMC, 2019-12-01)BACKGROUND: Adaptive designs are a wide class of methods focused on improving the power, efficiency and participant benefit of clinical trials. They do this through allowing information gathered during the trial to be used ... -
Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials.
Silva, RB; Yap, C; Carvajal, R; Lee, SM (LIPPINCOTT WILLIAMS & WILKINS, 2021-06-01)UNLABELLED: Simulation studies have shown that novel designs such as the continual reassessment method and the Bayesian optimal interval (BOIN) design outperform the 3 + 3 design by recommending the maximum tolerated dose ...